| Bioactivity | CDK9-IN-18 is a potent CDK9 inhibitor. CDK9-IN-18 blocks the phosphorylation function of kinase CDK9. CDK9-IN-18 exhibits both good anticancer activity and low cellular activity. CDK9-IN-18 induces apoptosis. |
| Invitro | CDK9-IN-18 (compound 12i) (0-20 μM, 3 hours; NH2 cells) suppress both HIV-1 transcription and the phosphorylation at Serine 2 of the RNAPII CTD in a dose-dependent manner[1].CDK9-IN-18 (compound 12i) (0-5.0 μM, 24 hours; human tumor cell lines) exerts antiproliferative effect through the induction of apoptosis in HepG2 cells[1]. Western Blot Analysis[1] Cell Line: |
| Name | CDK9-IN-18 |
| CAS | 1804127-83-0 |
| Formula | C27H20N8O |
| Molar Mass | 472.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hu H, et al. Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors. Bioorg Chem. 2020 Sep;102:104064. |
CDK9-IN-18
CAS: 1804127-83-0 F: C27H20N8O W: 472.50
CDK9-IN-18 is a potent CDK9 inhibitor. CDK9-IN-18 blocks the phosphorylation function of kinase CDK9. CDK9-IN-18 exhibit
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.